The troubled British Biotech and three former directors will receive a severe admonishment from the US Securities and Exchange Commission, drawing to an end a two-year inquiry into whether press releases issued by the company were too optimistic. Contrary to expectations, the SEC will not recommend fines or imprisonment of the former directors. The SEC was concerned that British Biotech omitted the views of the Federal Drug Authority on cancer antigens in some press releases. The company is also waiting for results of a London Stock Exchange inquiry. The recently merged AstraZeneca unveiled their new logo last week. Designed by branding agency Interbrand Newell & Sorrell, the logo is an attempt to convey the nature of the company's business by combining the A and Z with the familiar DNA spiral. The colours used, described as terracotta on purple, is allegedly softer and more 'human' than the hard blues and greens used by many pharmaceutical companies.
Selected biotech news
BioNews
The troubled British Biotech and three former directors will receive a severe admonishment from the US Securities and Exchange Commission, drawing to an end a two-year inquiry into whether press releases issued by the company were too optimistic. Contrary to expectations, the SEC will not recommend fines or imprisonment of...
Leave a Reply
You must be logged in to post a comment.